Evidence map›Paper›PMID 33317568›Full record

ArticleSubstance abuse treatment, prevention, and policy2020

Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016-2020.

Jørn Henrik Vold, Rolf Gjestad, Christer F Aas, Fatemeh Chalabianloo, Svetlana Skurtveit, Else-Marie Løberg, Kjell Arne Johansson, Lars Thore Fadnes, INTRO-HCV Study Group

Abstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jørn Henrik VoldDepartment of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021, Bergen, Norway. jorn.vold@uib.no.ORCID 0000-0001-8701-7638
Rolf GjestadDepartment of Psychiatry, Haukeland University Hospital, Bergen, Norway.
Christer F AasDepartment of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021, Bergen, Norway.
Fatemeh ChalabianlooDepartment of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021, Bergen, Norway.
Svetlana SkurtveitDepartment of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.
Else-Marie LøbergDepartment of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021, Bergen, Norway.
Kjell Arne JohanssonDepartment of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021, Bergen, Norway.
Lars Thore FadnesDepartment of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021, Bergen, Norway.
INTRO-HCV Study Group

Funding

Norges Forskningsråd 269855
6 · The paper itself

Abstract

backgroundThe impact of clinical and sociodemographic factors on fatigue remains unknown among patients with substance use disorders (SUD). This study aims to evaluate fatigue among patients with SUD using a nine-item fatigue severity scale (FSS-9) and identify the impact that clinical and sociodemographic factors - such as injecting substance use, chronic infectious diseases, liver fibrosis, opioid agonist therapy (OAT), debt difficulties, and housing situation - have on fatigue.

methodsWe used data from a cohort of patients with SUD in Norway with annual health assessments surveying FSS-9 and some clinical and sociodemographic factors. A total of 915 FSS-9 measurements were collected from 654 patients during the period 2016-2020. We defined baseline as the first annual health assessment when the health assessments were listed chronologically. Time was defined as years from baseline. We used a linear mixed model to analyse whether the clinical and sociodemographic factors affected the FSS-9 sum score, presented with beta coefficients (β) with 95% confidence intervals (CI).

resultsThe mean sum score of the FSS-9 was 43 (standard deviation: 16) at baseline. Females compared with males (adjusted mean difference of FSS-9 sum score: 4.1, 95% CI: 1.3-7.0), having debt difficulties compared with having no debt difficulties (2.9;0.4-5.3), and frequent use of benzodiazepines (5.7;3.0-8.4) or amphetamines (-5.0;-8.0- -2.0) compared to less frequent or no use of these substances changed the FSS-9 baseline sum score. The other clinical and sociodemographic factors did not predict any clinically relevant change in the FSS-9 sum score from baseline to the following health assessments.

conclusionPatients with SUD suffer from high levels of fatigue. Female patients, patients with debt difficulties, and those with extensive use of benzodiazepines are at particular risk of being fatigued. This should be taken into consideration when planning health services.

Indexed as

Socioeconomic FactorsAdolescentAdultCommunicable DiseasesFatigueFemaleHealth StatusHumansLiver CirrhosisMaleMental HealthMiddle AgedNorwayOpiate Substitution TreatmentSeverity of Illness IndexSubstance Abuse, IntravenousComorbiditiesFatigueFatigue severity scaleHIVIllicit drugsKidney diseaseQuality of lifeSubstance-related disordersViral human hepatitis

Identifiers

PMID33317568
PMCPMC7737389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.